In the IDF Congress, it revealed the results of the phase 3 clinical trial of Zemiglo
LG Chem has demonstrated that the company’s product Zemiglo has a strong blood sugar lowering effect on patients with difficulty in controlling blood sugar levels.
LG Chem announced on Dec. 7 that it participated in the IDF Congress held online as an abstract presenter and revealed the results of the phase 3 clinical trial of the Zemiglo additional triple-combination therapy.
The clinical trial was named ‘Solution’ study, containing the meaning that it will present a new drug combination that can maximize the blood sugar lowering effects on diabetic patients.
In this clinical trial, 315 patients with type 2 diabetes who are currently taking metmorfin, a first-line medication for type 2 diabetes, and dapagliflozin, the newest form of SGLT-2 inhibitor, were additionally treated with Zemiglo or a placebo for 24 weeks and then compared for glycated hemoglobin (HbA1c).
The change in glycated hemoglobin compared to the baseline in the 24th week was -0.86% for the group treated with Zemiglo and -0.20% for the group treated with a placebo, demonstrating that the blood sugar lowering effects of Zemiglo were superior to that of the placebo. The incidence of adverse effects, including hypoglycemia, was not significantly different from the placebo group, the company said.